CAMP
CAMP4 Therapeutics·NASDAQ
--
--(--)
--
--(--)
4.60 / 10
Netural
Fund flow evaluation is 7.35/10, classified as favorable, with Small-scale inflows showing a positive trend despite negative signals in larger blocks. Analyst coverage is limited to three institutions; two recent ratings are Buy (66.7%) and one is Neutral (33.3%), producing a weighted rating of 1.85 and a MarketComprehensiveAnalysis indicating mismatched expectations. The recent 8.6% drop from a $30 million share offering adds near-term pressure. Together, the strong fund flow and mixed analyst sentiment create a neutral-to-slightly-positive sentiment backdrop that partially offsets the weak fundamentals and technicals.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
67%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-09-16
InstitutionJP Morgan
Times predicted1
Historical Win Rate0.0%
What is the market sentiment for CAMP?
- CAMP holds a Bearish analyst rating, with 67% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 4.60/10 (Netural).
